Total revenues

Gilead Sciences·Products & Services·24 segments·Rolls up to Total Revenue

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Biktarvy	$3.23B	$3.47B	$3.77B	$3.15B	$3.53B	$3.69B	$3.97B	$3.36B
Descovy	$485M	$586M	$617M	$586M	$653M	$701M	$819M	$807M
Trodelvy	$320M	$332M	$355M	$293M	$364M	$357M	$384M	$402M
Yescarta	$414M	$387M	$389M	$386M	$393M	$349M	$368M	$332M
Sofosbuvir/Velpatasvir	$476M	$385M	$330M	$346M	$342M	$309M	$276M	$283M
Genvoya	$440M	$449M	$470M	$364M	$377M	$377M	$380M	$264M
Vemlidy	$243M	$232M	$260M	$252M	$252M	$280M	$287M	$237M
Odefsey	$315M	$326M	$336M	$281M	$298M	$277M	$310M	$221M
Yeztugo	—	—	—	—	—	—	—	$166M
Veklury	$214M	$692M	$338M	$302M	$121M	$277M	$211M	$144M
Symtuza - Revenue share	—	—	—	$114M	$124M	$124M	$133M	$138M
AmBisome	$151M	$130M	$109M	$139M	$129M	$123M	$118M	$138M
Livdelzi	—	—	—	—	—	—	—	$133M
Other Liver Disease	$113M	$116M	$130M	$121M	$201M	$231M	$281M	$114M
Tecartus	$107M	$98M	$98M	$78M	$92M	$83M	$90M	$75M
Other HIV	$105M	$100M	$112M	$91M	$107M	$112M	$190M	$73M
Other	$130M	$71M	$75M	$70M	$73M	$61M	$86M	$58M
Royalty, contract and other revenues	$41M	$30M	$33M	$54M	$27M	$424M	$22M	$14M
Total	$6.95B	$7.55B	$7.57B	$6.67B	$7.08B	$7.77B	$7.93B	$6.96B